The Application of Transcriptomics in the Treatment of Ulcerative Colitis With Ustekinumab

Ulcerative Colitis Clinical Trial

Official title:

The Application of Transcriptomics for Establishing Potential Prognostic Markers of Response to Treatment of Ulcerative Colitis With Ustekinumab

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05896943
• Other study ID #: 479/15-12-2022
• Status: Active, not recruiting
• Start date: April 1, 2022
• Est. completion date: June 30, 2024

Study information

• Verified date: February 2024
• Source: Evangelismos Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators hope that the present study will highlight new transcriptomic prognostic markers of response to Ustekinumab with the ultimate goal of individualizing treatment and making a more targeted selection of UC patients who will benefit from this biological agent.

Description:

Introduction: Optimizing treatment with biological agents is an ideal goal for patients with ulcerative colitis (UC). At present, there are insufficient prognostic markers of response to each biological agent, which makes it difficult to individualize treatment. Recent data suggest that mucosal inflammation patterns and serum cytokine profiles differ between patients who respond and those who do not. These studies mainly focused on anti-TNFα agents and Vedolizumab, while there are no corresponding data for Ustekinumab, which is a monoclonal antibody to interleukins 12 and 23 and has recently been approved for the treatment of patients with UC.

Aim of the study: To highlight prognostic markers of response (clinical and endoscopic) to Ustekinumab, in patients with UC, utilizing information from their transcriptome before starting treatment.

Methods: This is a prospective, single-center cohort study that will evaluate transcriptomic markers of response to Ustekinumab in patients with active UC. The diagnosis of the disease will be based on the established clinical, endoscopic and histological criteria. The patients' recruitment will begin in April 2022, while their consent will be required. The duration of follow-up of patients will be at least 6 months from the start of biological treatment. Patients will undergo endoscopy (sigmoidoscopy or total colonoscopy) with a biopsy of the orthosigmoid before the start of biological treatment and a repeat endoscopy 6 months later. The RNA profile of the patients will be recorded after isolation of the total RNA from colon biopsies. Then, using biostatistics, the transcriptomic profiles of patients who responded to Ustekinumab and those who did not respond to 6 months of treatment, will be compared.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 38
• Est. completion date: June 30, 2024
• Est. primary completion date: October 31, 2023
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Active UC in accordance with applicable diagnostic criteria [25] •

• Aged 18 or above

Exclusion Criteria:

• Prior surgical history for UC

• Toxic megacolon

• Infectious complications (Cl. Difficile, CMV infection)

• Patients who received any approved biologic agent (e.g. Infliximab, adalimumab, vedolizumab, golimumab) within the previous 8 weeks or any investigational biologic or other agent in the last 35 days

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer
• Ulcerative Colitis

Intervention

Drug:
• Ustekinumab
Patients with ulcerative colitis treated with ustekinumab

Locations

Country	Name	City	State
Greece	Evangelismos Hospital	Athens	Attiki

Sponsors (1)

Lead Sponsor	Collaborator
Evangelismos Hospital

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the rate of clinical remission	Total Mayo score of 2 or lower and no subscore higher than 1	6 months
Secondary	Endoscopic response rate	Reduction of the endoscopic Mayo subscore =1	6 months
Secondary	Clinical response rate	Reduction in the Mayo score of at least 3 points and a decrease of at least 30% from the baseline score, with a decrease of at least 1 point on the rectal bleeding subscale or an Absolute rectal bleeding score of 0 or 1	6 months
Secondary	Endoscopic remission rate	Endoscopic Mayo subscore 0	6 months